Toxins 2010, 2(6), 1568-1581; doi:10.3390/toxins2061568
Review

Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview)

1email and 2,* email
Received: 18 April 2010; in revised form: 17 June 2010 / Accepted: 18 June 2010 / Published: 21 June 2010
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: While intensive efforts have been made for the treatment of cancer, this disease is still the second leading cause of death in many countries. Metastatic breast cancer, late-stage colon cancer, malignant melanoma, multiple myeloma, and other forms of cancer are still essentially incurable in most cases. Recent advances in genomic technologies have permitted the simultaneous evaluation of DNA sequence-based alterations together with copy number gains and losses. The requirement for a multi-targeting approach is the common theme that emerges from these studies. Therefore, the combination of new targeted biological and cytotoxic agents is currently under investigation in multimodal treatment regimens. Similarly, a combinational principle is applied in traditional Chinese medicine, as formulas consist of several types of medicinal herbs or minerals, in which one represents the principal component, and the others serve as adjuvant ones that assist the effects, or facilitate the delivery, of the principal component. In Western medicine, approximately 60 different arsenic preparations have been developed and used in pharmacological history. In traditional Chinese medicines, different forms of mineral arsenicals (orpiment—As2S3, realgar—As4S4, and arsenolite—arsenic trioxide, As2O3) are used, and realgar alone is included in 22 oral remedies that are recognized by the Chinese Pharmacopeia Committee (2005). It is known that a significant portion of some forms of mineral arsenicals is poorly absorbed into the body, and would be unavailable to cause systemic damage. This review primary focuses on the application of arsenic sulfide (realgar) for treatment of various forms of cancer in vitro and in vivo.
Keywords: arsenic sulfide; realgar; cancer; nanoparticle; milling
PDF Full-text Download PDF Full-Text [180 KB, uploaded 21 June 2010 13:31 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Baláž, P.; Sedlák, J. Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview). Toxins 2010, 2, 1568-1581.

AMA Style

Baláž P, Sedlák J. Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview). Toxins. 2010; 2(6):1568-1581.

Chicago/Turabian Style

Baláž, Peter; Sedlák, Ján. 2010. "Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview)." Toxins 2, no. 6: 1568-1581.

Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert